The US Biomedical Advanced Research and Development Authority will provide up to $1.2 billion to AstraZeneca to accelerate work on an adenoviral vector vaccine for COVID-19 that the UK drug firm licensed from the University of Oxford. The UK government is providing about $80 million to the effort. AstraZeneca says it has finalized agreements for at least 400 million doses of the vaccine, AZD1222, and has secured production capacity for 1 billion doses. Deliveries could begin in September under a fair allocation program the firm is developing.
C&EN has made this story and all of its coverage of the coronavirus epidemic freely available during the outbreak to keep the public informed. To support our journalism, become a member of ACS or sign up for C&EN's weekly newsletter.